Trial Profile
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 16 Nov 2018 Planned End Date changed from 25 Mar 2019 to 18 Feb 2019.
- 16 Nov 2018 Status changed from recruiting to active, no longer recruiting.